| INTRODUC TI ON
Respiratory syncytial virus (RSV) is an important cause of respiratory infections, with the most severe infections occurring in young children, older adults, and adults with chronic co-morbidities. 1, 2 Acute lower respiratory infections (bronchiolitis and pneumonia) due to RSV are among the most common causes of hospital admission (estimated 3.2 million annually) and hospital deaths (estimated 59 600) in young children globally and are associated with a high hospitalization cost burden. 3, 4 The overall number of deaths associated with RSV is less certain but has been estimated to be between 94 600 and 149 400 deaths in young children globally. 5 RSV disease in young children has been associated with persisting sequelae such as recurrent wheeze and asthma later in childhood. 6 The burden of severe disease and deaths from RSV in high-risk adults remains uncertain but initial estimates suggest that influenza virus is more common than RSV, but RSV infection has a higher risk of death than seasonal influenza in adults. 7 The RSV vaccine development landscape is evolving rapidly. There are currently several vaccine candidates and monoclonal antibodies in various stages of clinical trials. 8, 9 The World Health Organization (WHO) Product Development for
Vaccines Advisory Committee assessed RSV as the most promising new vaccine of potential major public health importance that may be ready for widespread implementation in the next 10 years. 10 A gap analysis indicates that most data on RSV disease symptoms, treatment, and acute sequelae are from high-income countries in contrast to the RSV burden distribution. RSV disease data from low-and middle-income countries (LMICs) are improving, but additional data and granularity are needed particularly on disease in the first 6 months of life. 11 The Gavi Vaccine Alliance approved RSV immunization products in its Vaccine Investment Strategy for 2021-25 contingent on availability of a licenced product, a SAGE recommendation, WHO pre-qualification, and meeting the financial assumptions used as the basis of the RSV investment case. 12 Given the importance of RSV as a significant cause of hospitalization and death in young children, it is likthat a cost-effective vaccine would be considered for inclusion in national immunization programs globally. The Global Influenza Surveillance and Response System (GISRS) coordinated by WHO and endorsed by national governments tests more than two million respiratory specimens annually to monitor the spread and evolution of influenza viruses through a network of about 150 well-established laboratories in 114 countries representing 91% of the world's population. The GISRS network is ideally placed as a platform for the introduction of a more systematic testing for RSV associated with respiratory illness as it already uses molecular diagnostics on respiratory specimens and conditioned to report regular and disciplined reporting to a global platform.
Countries in Latin America and the Caribbean region started test-
ing for RSV by immunofluorescence. As RSV molecular diagnostics became widely available, many countries within the GISRS started testing for RSV and other respiratory viruses as a by-product of influenza surveillance using the WHO-recommended influenza-like illness (ILI), acute respiratory infection (ARI), and severe acute respiratory infection (SARI) case definitions (Table 1) External Quality Assurance program. The WHO FluMart data platform was adapted to receive case-based RSV data and visualize interactive visualization outputs.
Results: Laboratory standards for detecting RSV by RT-PCR were developed. A review assessed the feasibility and the low incremental costs for RSV surveillance. Several challenges were addressed related to case definitions, sampling strategies, the need to focus surveillance on young children, and the data required for burden estimation.
Conclusions:
There was no evidence of any significant adverse impact on the functioning of GISRS which is primarily intended for virologic and epidemiological surveillance of influenza. 15 These countries were selected in consultation with the WHO regional offices based on existing and strong capacities in laboratory and epidemiological surveillance and willingness to participate in the pilot. The overall aim of the pilot was to investigate the suitability of the GISRS platform for RSV surveillance in a range of settings. This paper describes the strategy and discusses how various epidemiological and laboratory challenges were addressed.
| PILOTING THE S TR ATEGY FOR R S V SURVEILL AN CE
The overall strategy aimed to leverage and build on the existing capacities of the well-established GISRS to test for RSV without adversely affecting its vital role in influenza surveillance. 15 The con- 
| OPP ORTUNITIE S AND CHALLENG E S
The RSV surveillance strategy aims to leverage existing national resources of the GISRS without adversely impacting its established Advocacy tools and approaches developed in the pilot, to raise awareness of RSV among the government, medical profession, and community, can be used in future communications, for example, to communicate the importance of influenza in different settings and age groups.
| Epidemiology-related challenges
Five major epidemiological concerns were identified for using GISRS for RSV surveillance. First, an ILI, ARI, or SARI case definition that requires fever would have low sensitivity to detect RSV, as over half of young children with RSV infection present without fever. 17, 18 Furthermore, non-respiratory presentations of RSV infection in very young infants are recognized (apnea, sepsis with no apparent cause) and a wider case definition would be needed in this age group. 19, 20 The pilot addressed this concern by using extended SARI and ARI case definitions (which do not include fever) for hospital-based and community-based surveillance, respectively. In addition, the case definition for infants aged less than 6 months included apnea and sepsis from undetermined cause (Table 1) . Second, the RSV disease burden is highest in children aged less than 2 years, 21 an age group historically underrepresented in influenza surveillance by the GISRS. The pilot addressed this concern with quota sampling that required each country to recruit and test 1000 eligible patients per
year (about 20 per week) stratified equally across four age groups viz. less than 6 months, 6 months to less than 5 years, 5 to less than 65 years, and 65 years and above. This would allow an RSV prevalence of 5%-10% to be detected with a 95% confidence interval in each of the age groups. Countries were encouraged to add pediatric wards and hospitals, and neonatal and pediatric intensive care units to their existing GISRS sentinel sites. Third, RSV seasonality is not fully understood globally. Even where it is, seasonality may vary year to year and differ in timing from that of influenza [22] [23] [24] ; thus, GISRS sampling confined to the influenza season may miss many RSV cases.
The pilot addressed this concern through year-round surveillance for RSV in contrast to influenza surveillance which in some countries is restricted to the influenza season. Fourth, estimation of the popula- 
| Laboratory-related challenges
Three major laboratory-related concerns were considered. First, most NICs were already testing for RSV and other respiratory viruses using commercial or laboratory-developed molecular diagnostics, either monoplex or multiplex RT-PCR assays as well as antigenbased testing methods that varied in sensitivity and specificity.
Laboratories in Latin America were using direct or indirect immunofluorescence assay (IFA) to detect RSV, the sensitivity and specificity of which varies with the age of the patient, and type and quality of specimen. The sensitivity of IFA might be low for RSV detection especially in the off-season period. 26, 27 All laboratories agreed to use 
| D ISCUSS I ON
The overarching aim of the pilot was to build on the successful global influenza surveillance platform, GISRS, to obtain RSV surveillance data without having a negative impact on GISRS. The primary motivation was to establish systems to obtain data to inform policy and decision making for possible future RSV vaccine investment, especially in LMIC settings in which it may be unlikely that there will be other relevant sources of suitable RSV data for this purpose. A midterm review assessed that it was feasible to leverage GISRS for RSV surveillance with little incremental cost without any significant adverse impact on the functioning of GISRS for influenza surveillance.
We have outlined the major challenges faced, and the decisions made to tackle these in the development of the RSV surveillance pilot approach. The pilot collected data to monitor performance at each site and will be able to report on the degree of success achieved using the approach adopted. For example, the pilot will report on the relative performance of the case definitions for the identification of RSV and influenza cases in hospital and primary care settings and will monitor the success in recruitment of cases in the specific targeted high-risk groups. A limitation of the current pilot is that it did not specifically target pregnant women for RSV surveillance. Although two studies from Nepal and South Africa have reported that RSV infection during pregnancy does not adversely affect the pregnancy outcomes nor that post-partum RSV infection of neonates cause severe disease, 31 RSV surveillance in pregnant women should be considered for inclusion in some sites in future extensions of the global pilot. An important additional resource required (beyond that for GISRS) is the ability to report data from individual cases. This will help assess the validity of changes to the surveillance case definitions adopted and will help describe atypical case presentations, for example, in older adults and infants.
This should help guide future decisions about how future RSV surveillance should be conducted and inform the design of studies of vaccine effectiveness. Initial feedback suggests that many sites will have to expand their existing GISRS hospital surveillance to include more pediatric hospitals, and those that admit neonates and young infants so that this important risk group is adequately represented.
Enhanced data on respiratory support required during hospitalization will also assist in assessment of the health costs associated with RSV. These data will be important in health economical assessments of any intervention (such as vaccines). Equally, it will be important to raise awareness of the possibility of RSV infection in causing the respiratory disorders in older adults and those with chronic medical conditions.
Once RSV seasonality is better defined, it may be possible to limit site-specific surveillance to high transmission seasons for both RSV and influenza. Once RSV case definitions have been evaluated, the need for ongoing individual case data will be reconsidered.
Multiyear data from RSV surveillance will allow the study of evolutionary changes in RSV over time and in response to widespread vaccine introduction.
An important aspect of the pilot is the collection of surveillance data on RSV and influenza in both primary and secondary care settings. This is important as coinfection in causation of lower respiratory infections is increasingly recognized. 32 This joint surveillance will help improve knowledge of RSV and influenza global transmission patterns and will inform future considerations of the need for and feasibility of broader infectious disease surveillance platforms which could encompass several other important respiratory pathogens that can result in hospitalization.
A major advantage of using the existing GISRS platform is that GISRS has built close relationships with Ministries of Health and policymakers in individual countries. This is clearly signaled by the financial support to the RSV surveillance pilot provided by national GISRS platforms. The pilot served to strengthen these relationships by providing policymakers with information on RSV from which vaccine investment, healthcare planning decision, and cost-benefit analyses can be made in the future. We expect that these data raise awareness of RSV as one of the most common causes of hospitalization in young children globally and an underappreciated cause of disease in older adults. We will work closely with other stakeholders in each country to ensure that these data are presented to the appropriate audiences and respond to local comments and needs.
Another possible approach to long-term sustainability may be to Finally, the pilot phase did not track mortality or focus on severity of illness and did not follow up subjects for long-term sequelae such as wheeze or asthma, or conduct surveillance in pregnant women to assess the impact of RSV infection on pregnancy and birth outcomes, which could be a limitation or an opportunity to explore, when RSV surveillance is established using lessons learnt from the pilot phase.
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